<DOC>
	<DOCNO>NCT01525238</DOCNO>
	<brief_summary>The primary purpose study evaluate pharmacokinetics ( PK ) Dapagliflozin pediatric subject type 2 diabetes mellitus ( T2DM )</brief_summary>
	<brief_title>PK Study Dapagliflozin Pediatric Subjects With T2DM</brief_title>
	<detailed_description>Primary purpose : The primary purpose ass pharmacokinetics single dose Dapagliflozin range 2.5 10 mg pediatric subject age 10 17 year T2DM</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Clinical diagnosis T2DM Male female subject age 1017 Glycosylated Hemoglobin A1c ( HbA1c ) &gt; 6 &lt; 10 % Fasting plasma glucose ( FPG ) &gt; 240 mg/dL screen Abnormal renal function Active liver disease and/or significant abnormal liver function</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>